Healthcare Professionals, click here
This site is intended for US residents only.

RESOLUTE® is a Phase 1/2 Investigational Gene Transfer Study for Adults with Late-Onset Pompe Disease (LOPD)

RESOLUTE® Study Update

Enrollment is complete for the first cohort of the RESOLUTE® (Phase 1/2) study of investigational SPK-3006 for treatment of Late-Onset Pompe Disease. For details on participating in RESOLUTE®, please speak with your physician or contact us at https://sparktx.com/medinfo/

What is Pompe Disease?

Pompe disease is a lysosomal storage disorder and neuromuscular disease, with systemic, multi-organ manifestations resulting from mutations in the gene encoding acid alpha-glucosidase (GAA). The disease is oftentimes life-limiting and can be fatal. Mutations in the gene prevent the GAA enzyme from breaking down the energy storage molecule, glycogen, effectively. This allows glycogen to build up to toxic levels in lysosomes, which are common structures known as organelles found in cells in the body. This can damage organs and tissues throughout the body, particularly in muscles, causing Pompe disease.

What is RESOLUTE®?

RESOLUTE® is a clinical study of an investigational gene therapy (also referred to as gene transfer) called SPK-3006. It is being studied as a potential treatment for adults living with LOPD. Different doses of SPK-3006 are being studied with the goal of finding which dose, if any, may be safe and effective. Each participant will receive one of the doses, one time.

Questions? Contact us at https://sparktx.com/medinfo/.

Is this study right for me?

Age: 18+ | Genders: Male and Female

Accepts Healthy Volunteers: No

Entry Criteria
The RESOLUTE® clinical trial is recruiting men and women who have LOPD. In order to be considered for the trial, participants must:

  • have clinical symptoms of LOPD affecting daily living and have received Enzyme Replacement Therapy (ERT) for at least the past 24 months (2 years)
  • agree to use reliable birth control
  • not have any liver disease
  • have not recieved any gene therapy before

This is not a complete list of requirements to be considered for participation in the RESOLUTE® clinical trial. For more details, please speak with your physician, visit ClinicalTrials.gov, or contact us at RESOLUTE@sparktx.com.

NCT04093349 (ClinicalTrials.gov) | SPK-3006-101 | 2019-001283-30 (EudraCT Number)

What should I expect if I participate in this clinical study?

Participating in this clinical study requires a variety of tests and you will be monitored throughout the study. Through these medical tests, the research team will learn how your body responds to the investigational gene therapy, the safety of the gene therapy, and how well the gene therapy may be working in your body.

There are 3 defined periods in the study:

  1. Screening period: when participant eligibility is determined
  2. Dosing day: a one-time IV infusion of investigational SPK-3006
  3. Follow-up: physical examination and functional testing is conducted for about 52 weeks after receiving investigational SPK-3006

Due to COVID-19 (SARS-CoV-2), the schedule of assessments currently included in the study protocol has been carefully evaluated to minimize visits to study sites. Whenever possible, certain study assessments take place in the participant’s home to reduce the burden of participation in the study.

Long term follow up in gene therapy clinical studies:

While the first phase of a gene therapy study may last a year or so, gene therapy studies often involve long-term follow-up over several years. Long-term follow-up is critical to understanding the potential benefits and risks of investigational gene therapy over time. Given that gene therapy research is relatively new, there is still much to learn about the long-term effects of investigational gene therapy, including how long a treatment may be considered effective and if there are any side effects that occur later on. Long-term follow up of clinical study participants provides an important pathway to that understanding. When deciding if participation in an investigational gene therapy clinical study is right for you, the expected long-term follow-up will be important for you to consider.

Where are the study locations?

Clinical study sites are active and enrolling. If you are interested in learning more, and to view current site locations, please visit the RESOLUTE® study listing on ClinicalTrials.gov

What is investigational gene therapy?

Gene therapy is a potential approach to treating or preventing genetic diseases. The goal of gene therapy is to address a genetic disease at its source—the gene. This can be done by modifying (changing) genes or creating new functional genes in a laboratory and delivering them to specific cells in the body.

"Investigational" means that the safety and effectiveness of the gene therapy have not been established, and that it is not approved by the Food and Drug Administration (FDA) or other regulatory agency.

Scientists have been investigating gene therapy for more than 50 years, and the science around gene therapy continues to evolve. To date, more than 2,600 gene therapy clinical trials are planned, ongoing, or have been completed for different genetic diseases.

Gene therapy is an approach being investigated for use in Pompe disease. This approach introduces a new functional copy of a gene with the aim of restoring or enhancing its original function. It is sometimes referred to as gene augmentation, gene transfer, or gene replacement. View the video to learn more about one approach to gene therapy for Pompe disease.